Figure 6: C391 Reduces airway leukocyte recruitment in C57Bl/6
and BALB/c murine asthma models.
(A - D) Quantification of bronchoalveolar lavage fluid (BALF)
cell counts in C57Bl/6 (A,B) and BALB/c (C, D ) as
follows: (A, C ) total cells; (B, D) neutrophils,
eosinophils, lymphocytes, and macrophages (with macrophage
quantification shown on the right y- axis). A. alternatatreatment significantly increased total cell infiltration, and
specifically the recruitment of eosinophils and lymphocytes in both
mouse strains, as well as increased macrophages in BALB/c. Eosinophils
and lymphocytes in C57Bl/6 were significantly attenuated in A.
alternata exposed mice treated with C391, and lymphocytes and
macrophages were significantly attenuated in A. alternata exposed
mice treated with C391 in BALB/c. * Indicates significant difference
between HBSS treated and A. alternata exposed mice; p ≤ 0.05 . #
Indicates significant difference between A. alternata exposed
mice and A. alternata exposed mice treated with C391; p ≤ 0.05.
Figure
7: C391 reduces airway hyperresponsiveness in a BALB/c murine asthma
model.
BALB/c mice were given nasal instillations of treatment (HBSS control,A. alternata or A. alternata with C391) on days 0, 3, 6
and forced oscillation technique with methacholine challenge to measure
lung resistance was performed on day 8. The percent change in maximum
total airway resistance (Max Rrs) is reported. A.
alternata treatment increases Max Rrs measurements over control.
However, A. alternata treatment in the presence of C391 the Max
Rrs are similar to control. n ≥ 4 for each treatment. * Indicates
significant difference between HBSS treated and A. alternataexposed mice; p ≤ 0.05. # Indicates significant difference betweenA. alternata exposed mice and A. alterna ta exposed mice
treated with C391; p ≤ 0.05.